Altering the potential of nanoencapsulation formulation and digitized transdermal patch combination as a minimal invasive treatment for breast cancer

Background: Breast cancer is a leading cause of cancer-related mortality, accounting for 25% of cancer deaths globally. Despite advances in surgical therapies like lumpectomy, mastectomy, and lymph node dissection, these interventions pose significant risks, including bleeding, infections, and incomplete tumor removal, leading to recurrence. Innovative strategies like nanotechnology integrated with digitalized systems and transdermal patches hold promise for improving treatment outcomes. Methods: This review explored the potential of nanoencapsulation combined with transdermal delivery and digitalization as a breast cancer therapy. Literature from databases such as PubMed and ScienceDirect, published between 2019 and 2024, was analyzed, focusing on advances in nanotechnology, drug delivery systems, and digitalized therapy. Eleven highly relevant articles informed this review. Results: The proposed system utilizes nanoparticles for drug encapsulation, enhancing bioavailability and precision. Nanoparticles functionalized for targeted delivery exploit the Enhanced Permeability and Retention (EPR) effect and receptor-specific targeting, such as HER-2. Digital systems optimize drug release in real-time based on patient biomarkers, ensuring controlled and sustained therapy with minimal side effects. Transdermal patches serve as a practical delivery method, offering ease of use, reduced systemic side effects, and enhanced patient compliance. Conclusion: Integrating nanoencapsulation, digitalization, and transdermal patches provides a revolutionary approach to breast cancer treatment. This minimally invasive method improves therapeutic precision and patient outcomes, reducing the risks associated with conventional therapies. Further research and development are needed to translate this innovation into clinical practice.